In 2023, there were **** deaths from diabetes mellitus per 100,000 people in the United States. The death rate caused by this condition has fluctuated over the past decades, reaching almost ** deaths per 100,000 people in the early 2000s, and about ** deaths in 1980. Prevalence of diabetes In 2022, around *** percent of the adult population in the U.S. had diabetes. In total, around ** million adults in the United States are currently living with diabetes. Of this total, the vast majority were aged 45 years and older. The states with the highest share of adults with diabetes are West Virginia, Mississippi, and Louisiana. Cure for diabetes? Researchers are helping diabetics put their Type 2 diabetes into remission, where the blood sugar levels are kept within a healthy range. For Type 1, scientists are looking for ways to prevent the immune system’s attack on beta cells, which causes diabetes. These cells, located in the pancreas, produce the insulin people need to live. As of yet, there is no cure for diabetes mellitus; however, scientists are researching ways to make diabetes harmless one day.

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. This is the Type 1 Diabetes report. It details the findings and recommendations relating to diabetes care process completion, treatment target achievement and structured education for people with type 1 diabetes. The 2019-20 audit covers the period 01 January 2019 to 31 March 2020. This is the first NDA report dedicated to people with type 1 diabetes. A new diagnosis validation process, which considers medication as well as recorded diagnosis, has been introduced to try to ensure that only people with true type 1 diabetes are included (see appendix). Results are to be taken in the context of low data submission from specialist services, possibly hampered due to COVID-19.

Type 1 diabetes affects approximately ******* children worldwide, with ******* new cases diagnosed annually. This chronic condition, requiring lifelong insulin treatment, impacts a significant portion of the global child population of **** billion. Global diabetes trends and projections The impact of diabetes extends far beyond childhood, with the total number of diabetics worldwide expected to reach *** million by 2050. This projected increase corresponds to a rise in global diabetes prevalence from ** percent in 2024 to ** percent by 2050. The Western Pacific region currently has the highest number of diabetics, with approximately *** million people aged 20-79 affected. Africa, has the lowest number of diabetics with **** million in 2024. However, the number of diabetics in Africa is expected to increase significantly in the coming decades. Regional disparities and health concerns The global distribution of diabetes cases varies significantly, with Africa expected to see a *** percent increase in diabetes cases from 2024 to 2050, compared to a ** percent rise in North America and the Caribbean. As diabetes remains a critical health issue worldwide, it contributes to various complications and was the eighth leading cause of death globally in 2021, resulting in approximately **** million deaths that year.

Diabetes continues to be a significant global health concern, with the Western Pacific region reporting the highest number of diabetes-related deaths in 2024, with around 1.2 million. This stark figure underscores the urgent need for improved diabetes prevention and management strategies worldwide. North America and the Caribbean followed with an estimated 526,000 deaths, while Africa is had the lowest number at 216,000. Regional disparities and global impact The prevalence of diabetes varies significantly across regions, reflecting differences in healthcare systems, lifestyle factors, and genetic predispositions. In the United States, the death rate from diabetes mellitus was 22.4 per 100,000 people in 2023, with 8.4 percent of the adult population living with the condition. Canada has seen a slight decrease in its diabetes-related death rate, falling from 21.8 per 100,000 in 2000 to 18.1 per 100,000 in 2023. These figures highlight the ongoing challenges in managing diabetes, even in countries with advanced healthcare systems. European landscape and global context Within Europe, Germany reported the highest number of diabetes-related deaths in 2024, with nearly 63,000 fatalities among adults aged 20 to 79 years. Italy followed closely with around 62,400 deaths. However, Czechia reported the highest mortality rates in Europe as of 2022, with 43.4 diabetes deaths per 100,000 population overall. On a global scale, diabetes remains a major health concern, with 19 percent of adults worldwide identifying it as one of the biggest health problems in their country.

To reduce deaths from diabetes.

It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

BackgroundRandomized controlled trials have shown the importance of tight glucose control in type 1 diabetes (T1DM), but few recent studies have evaluated the risk of cardiovascular disease (CVD) and all-cause mortality among adults with T1DM. We evaluated these risks in adults with T1DM compared with the non-diabetic population in a nationwide study from Scotland and examined control of CVD risk factors in those with T1DM. Methods and FindingsThe Scottish Care Information-Diabetes Collaboration database was used to identify all people registered with T1DM and aged ≥20 years in 2005–2007 and to provide risk factor data. Major CVD events and deaths were obtained from the national hospital admissions database and death register. The age-adjusted incidence rate ratio (IRR) for CVD and mortality in T1DM (n = 21,789) versus the non-diabetic population (3.96 million) was estimated using Poisson regression. The age-adjusted IRR for first CVD event associated with T1DM versus the non-diabetic population was higher in women (3.0: 95% CI 2.4–3.8, p

In 2019, the mortality rate of chronic kidney disease due to type 2 diabetes in Germany was ***** per 100,000 population, the highest across the European countries shown. Furthermore, the mortality rate from kidney disease related to type 1 diabetes was highest in Portugal at **** per 100,000.

INTRODUCTION: Diabetic ketoacidosis (DKA) is one the main complications of type 1 diabetes mellitus (DM1) and the leading cause of death among children and adolescents with the disease. The Medical hospital of Ribeirão Preto Medical School (HC-FMRP) is a reference in pediatric endocrinology and is responsible for most of the treatment of DKA cases in the Unified Health System. The objective of this study was to characterize the cases of DKA treated in that service and identify their most frequent complications. RESEARCH DESIGN AND METHODS: A cross-sectional descriptive study was carried out, based on the review of medical records of patients aged 0 to 16 years with a diagnosis of DKA treated between January 2016 and August 2020. RESULTS: Seventy-seven (77) admissions were analyzed. In relation to the total, 55.84% were diagnosed with a new case of DM1. The most affected age group was teenagers. An increase of 90.9% of cases between 2016 and 2020 was visualized. In HCFMRP, insulin therapy is performed subcutaneously. In the study, an increase in the need for insulin use was observed as the severity increased. Hypokalemia was the most frequent complication. There was cerebral edema in 11.69% of the cases, and cerebral edema was the cause of the only death, corresponding to a mortality rate of 1.29%. CONCLUSIONS: DKA incidence rates were higher than those reported in current guidelines. The number of cerebral edemas was also higher, but with lower mortality. It shows the effectiveness of subcutaneous insulin for treatment. An increase in the number of DKA cases was seen over the period, and more studies are needed to evaluate it. Other studies are also necessary to evaluate the difference in therapeutic conduction with subcutaneous and intravenous insulin. This study can contribute to improvement in the DKA management.

Demographics of patients with childhood-onset type 1 diabetes at the age of 15 according to the specialty of their attending physicians.

aAll those aged ≥20 and observed in the period 2005–2007.SE, standard error.

AimsTo systematically review the evidence of socioeconomic inequalities for adults with type 1 diabetes in relation to mortality, morbidity and diabetes management.MethodsWe carried out a systematic search across six relevant databases and included all studies reporting associations between socioeconomic indicators and mortality, morbidity, or diabetes management for adults with type 1 diabetes. Data extraction and quality assessment was undertaken for all included studies. A narrative synthesis was conducted.ResultsA total of 33 studies were identified. Twelve cohort, 19 cross sectional and 2 case control studies met the inclusion criteria. Regardless of healthcare system, low socioeconomic status was associated with poorer outcomes. Following adjustments for other risk factors, socioeconomic status was a statistically significant independent predictor of mortality in 9/10 studies and morbidity in 8/10 studies for adults with type 1 diabetes. There appeared to be an association between low socioeconomic status and some aspects of diabetes management. Although only 3 of 16 studies made adjustments for confounders and other risk factors, poor diabetes management was associated with lower socioeconomic status in 3/3 of these studies.ConclusionsLow socioeconomic status is associated with higher levels of mortality and morbidity for adults with type 1 diabetes even amongst those with access to a universal healthcare system. The association between low socioeconomic status and diabetes management requires further research given the paucity of evidence and the potential for diabetes management to mitigate the adverse effects of low socioeconomic status.

BackgroundDistal symmetric polyneuropathy (DSPN) is a common microvascular complication of both type 1 and 2 diabetes with substantial morbidity burden and reduced quality of life. Its association with mortality is equivocal.PurposeTo describe the association between DSPN and all-cause mortality in people with diabetes and further stratify by the type of diabetes based on a meta-analysis of published observational studies.Data SourcesWe searched Medline from inception to May 2021.Study SelectionOriginal data were collected from case-control and cohort studies that reported on diabetes and DSPN status at baseline and all-cause mortality during follow-up.Data Extractionwas completed by diabetes specialists with clinical experience in neuropathy assessment.Data SynthesisData was synthesized using random-effects meta-analysis. The difference between type 1 and 2 diabetes was investigated using meta-regression.ResultsA total of 31 cohorts (n=155,934 participants, median 27.4% with DSPN at baseline, all-cause mortality 12.3%) were included. Diabetes patients with DSPN had an almost twofold mortality (HR: 1.96, 95%CI: 1.68-2.27, I2 = 91.7%), I2 = 91.7%) compared to those without DSPN that was partly explained by baseline risk factors (adjusted HR: 1.60, 95%CI: 1.37-1.87, I2 = 78.86%). The association was stronger in type 1 compared to type 2 diabetes (HR: 2.22, 95%CI: 1.43-3.45). Findings were robust in sensitivity analyses without significant publication bias.LimitationsNot all papers reported multiple adjusted estimates. The definition of DSPN was heterogeneous.ConclusionsDSPN is associated with an almost twofold risk of death. If this association is causal, targeted therapy for DSPN could improve life expectancy of diabetic patients.

Series Name: Number of deaths attributed to non-communicable diseases by type of disease and sex (number)Series Code: SH_DTH_NCDRelease Version: 2021.Q2.G.03 This dataset is part of the Global SDG Indicator Database compiled through the UN System in preparation for the Secretary-General's annual report on Progress towards the Sustainable Development Goals.Indicator 3.4.1: Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory diseaseTarget 3.4: By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-beingGoal 3: Ensure healthy lives and promote well-being for all at all agesFor more information on the compilation methodology of this dataset, see https://unstats.un.org/sdgs/metadata/

Overall rates and relative risks of all-cause and cardiovascular mortality by different levels of hypoglycemia in type 2 diabetic patients.

Background: Macro vascular complications occur very frequently in patients with type 2 diabetes mellitus (T2DM) with a high mortality rate, due to the development of cardiovascular disease (CVD), such as stroke, atherosclerosis acceleration, and atrial fibrillation. T2DM is a significant risk factor for CVD and has become the leading cause of death. The purpose of this study was to detect the early risk of macro vascular complications by using the ankle brachial index (ABI) as a marker.Method: This study was an analytic study with a cross-sectional approach. The study population was patients with T2DM from several primary health care centers in Medan. In total, 89 subjects who met the inclusion and exclusion criteria were recruited with consecutive sampling. ABI was determined as the ratio of systolic blood pressure in the brachial artery to the posterior tibial artery after the subjects had been relaxed and felt comfortable in a supine position. Examination of vitamin D and lipid profile was derived from examination of venous blood. Data were processed using SPSS and analyzed with one-way ANOVA.Results: The study found that there was a relationship between LDL-C, triglyceride, and vitamin D (25OH-D) based on the ABI (p > 0.05).Conclusions: ABI can be used for an early detection of macro vascular complications. Apart from being easy to perform, ABI was non-invasive. Some other risk factors that can also be used to assess complications and have relationships with ABI were LDL-C, triglyceride, and vitamin D (25OH-D). Complications in T2DM patients can be prevented with reasonable blood sugar control and lifestyle changes. Education and motivation need to be given to patients so that they become more independent in controlling their disease and improving their quality of life.

Background.

Diabetes mellitus affects over 3.9 million people in the United Kingdom (UK), with over 2.6 million people in England alone. Each year more than 1 million people with diabetes are acutely admitted to hospital due to complications of their illness. This includes Diabetic emergencies such as Diabetic Comas, Hypoglycaemia, Diabetic ketoacidosis, and Diabetic Hyperosmolar Hyperglycaemic State. Diabetic emergency management is often not compliant with national guidelines, and there is a pressing need to improve patient care. This dataset includes 65,506 people and 168,706 spells, designed to support research which improves diabetic emergency and unplanned care.

Other causes for admission include diabetic ulcers, neuropathies, kidney disease and associated co-morbidities such as infection, cerebrovascular disease and cardiovascular disease. This dataset includes acute all diabetic admissions to University Hospitals Birmingham NHS Trust from 2000 onwards refreshed to include new admissions as they occur.

PIONEER geography The West Midlands (WM) has a population of 5.9 million & includes a diverse ethnic & socio-economic mix.

EHR. UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & an expanded 250 ITU bed capacity during COVID. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”.

Scope: All patients admitted to hospital from year 2002 and onwards, curated to focus on Diabetes. Longitudinal & individually linked, so that the preceding & subsequent health journey can be mapped & healthcare utilisation prior to & after admission understood. The dataset includes highly granular patient demographics & co-morbidities taken from ICD-10 & SNOMED-CT codes. Serial, structured data pertaining to acute care process (timings, staff grades, specialty review, wards and triage). Along with presenting complaints, outpatients admissions, microbiology results, referrals, procedures, therapies, all physiology readings (pulse, blood pressure, respiratory rate, oxygen saturations and others), all blood results(urea, albumin, platelets, white blood cells and others). Includes all prescribed & administered treatments and all outcomes. Linked images are also available (radiographs, CT scans, MRI).

Available supplementary data: Matched controls; ambulance, OMOP data, synthetic data.

Available supplementary support: Analytics, Model build, validation & refinement; A.I.; Data partner support for ETL (extract, transform & load) process, Clinical expertise, Patient & end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.

Audit collects Information about general diabetes care. Data submitted by health care services, relevant to service they provide i.e. Secondary Care Bodies = Type 1, GP practices = Type 2. Includes demographics and diabetes relevant biometric information.

According to preliminary data between January and October 2024, *** percent of deaths in the Philippines were caused by diabetes mellitus diseases. Deaths from such illnesses peaked in 2020. Diabetes mellitus is diagnosed when glucose is high in the blood.

BackgroundChronic kidney disease (CKD) is a public health problem largely caused by diabetes. The epidemiology of diabetes mellitus–related CKD (CKD-DM) could provide specific support to lessen global, regional, and national CKD burden.MethodsData were derived from the GBD 2019 study, including four measures and age-standardized rates (ASRs). Estimated annual percentage changes and 95% CIs were calculated to evaluate the variation trend of ASRs.ResultsDiabetes caused the majority of new cases and patients with CKD in all regions. All ASRs for type 2 diabetes–related CKD increased over 30 years. Asia and Middle socio-demographic index (SDI) quintile always carried the heaviest burden of CKD-DM. Diabetes type 2 became the second leading cause of CKD and CKD-related death and the third leading cause of CKD-related DALYs in 2019. Type 2 diabetes–related CKD accounted for most of the CKD-DM disease burden. There were 2.62 million incident cases, 134.58 million patients, 405.99 thousand deaths, and 13.09 million disability-adjusted life-years (DALYs) of CKD-DM worldwide in 2019. Age-standardized incidence (ASIR) and prevalence rate (ASPR) of type 1 diabetes–related CKD increased, whereas age-standardized death rate (ASDR) and DALY rate decreased for females and increased for males. In high SDI quintile, ASIR and ASPR of type 1 diabetes–related CKD remained the highest, with the slowest increase, whereas the ASDR and age-standardized DALY rate remained the lowest there. In high SDI quintile, ASIR of type 2 diabetes–related CKD was the highest, with the lowest increasing rate. In addition, type 2 diabetes–related CKD occurred most in people aged 80-plus years worldwide. The main age of type 2 diabetes–related CKD patients was 55–64 years in Asia and Africa. The prevalence, mortality, and DALY rate of type 2 diabetes–related CKD increased with age. As for incidence, there was a peak at 80 years, and after age of 80, the incidence declined. CKD-DM-related anemia was mainly in mild to moderate grade.ConclusionsIncreasing burden of CKD-DM varied among regions and countries. Prevention and treatment measures should be strengthened according to CKD-DM epidemiology, especially in middle SDI quintile and Asia.